blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3030573

EP3030573 - MOLECULAR TARGETS FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS, HYPERTROPHIC SCARS OR KELOIDS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.09.2018
Database last updated on 16.07.2024
FormerThe patent has been granted
Status updated on  20.10.2017
FormerGrant of patent is intended
Status updated on  15.06.2017
FormerExamination is in progress
Status updated on  31.03.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL, IS		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Centre National de la Recherche Scientifique (C.N.R.S.)
3 rue Michel-Ange
75794 Paris Cedex 16 / FR
For all designated states
INSERM (Institut National de la Santé et de la Recherche Scientifique)
101 rue de Tolbiac
75654 Paris / FR
For all designated states
Urgo Recherche Innovation et Développement
42, rue de Longvic
21300 Chenove / FR
For all designated states
Université Paris Diderot - Paris 7
5 rue Thomas Mann
75013 Paris / FR
For all designated states
Ecole Normale Supérieure
45, rue d'Ulm
75005 Paris / FR
[2017/47]
Former [2016/24]For all designated states
Centre National de la Recherche Scientifique (CNRS)
3, rue Michel-Ange
75794 Paris Cedex 16 / FR
For all designated states
INSERM (Institut National de la Santé et de la Recherche Scientifique)
101 rue de Tolbiac
75654 Paris / FR
For all designated states
Urgo Recherche Innovation et Développement
42 Rue de Longvic
21300 Chenove / FR
For all designated states
Université Paris Diderot - Paris 7
5 rue Thomas Mann
75013 Paris / FR
For all designated states
Ecole Normale Supérieure
45, rue d'Ulm
75005 Paris / FR
Inventor(s)01 / DUGAST-DARZACQ, Claire
478 Michigan Ave
Berkeley, CA 94707 / US
02 / NOIZET, Maïté
16, rue Olivier de Serres
75015 Paris / FR
03 / DARZACQ, Xavier
478 Michigan Avenue
Berkeley, CA 94707 / US
 [2017/47]
Former [2016/24]01 / DUGAST-DARZACQ, Claire
478 Michigan Ave
Berkeley, CA 94707 / US
02 / NOIZET, Maïté
76-78 Avenue de Paris
Bâtiment Le Vau
F-78000 Versailles / FR
03 / DARZACQ, Xavier
24 Avenue Raymond Aron
F-92160 Antony / FR
Representative(s)Plasseraud IP
104 Rue de Richelieu
CS92104
75080 Paris Cedex 02 / FR
[N/P]
Former [2017/47]Cabinet Plasseraud
66, rue de la Chaussée d'Antin
75440 Paris Cedex 09 / FR
Former [2016/24]Cabinet Plasseraud
66, rue de la Chaussée d'Antin
75440 Paris Cedex 09 / FR
Application number, filing date14744577.930.07.2014
[2016/24]
WO2014EP66342
Priority number, dateWO2013IB0198905.08.2013         Original published format: PCT/IB2013/001989
[2016/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015018698
Date:12.02.2015
Language:EN
[2015/06]
Type: A1 Application with search report 
No.:EP3030573
Date:15.06.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 12.02.2015 takes the place of the publication of the European patent application.
[2016/24]
Type: B1 Patent specification 
No.:EP3030573
Date:22.11.2017
Language:EN
[2017/47]
Search report(s)International search report - published on:EP12.02.2015
ClassificationIPC:C07K14/47, C12N15/113, A61K48/00, A61K31/7088, A61K45/06, A61K31/713
[2017/26]
CPC:
C12N15/113 (EP,US); A61K31/713 (EP,US); A61K45/06 (EP,US);
A61P17/02 (EP); A61P43/00 (EP); C07K14/4702 (EP,US);
A61K2300/00 (US); C12N2310/14 (EP,US); C12N2320/12 (EP,US);
C12N2320/30 (US) (-)
C-Set:
A61K31/713, A61K2300/00 (EP,US)
Former IPC [2016/24]C07K14/47, C12N15/113, A61K48/00, A61K31/7088
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/24]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZIELMOLEKÜLE ZUR PRÄVENTION UND/ODER BEHANDLUNG VON FIBROSE, HYPERTROPHISCHEN NARBEN ODER KELOIDEN[2016/24]
English:MOLECULAR TARGETS FOR THE PREVENTION AND/OR TREATMENT OF FIBROSIS, HYPERTROPHIC SCARS OR KELOIDS[2016/24]
French:CIBLES MOLÉCULAIRES DESTINÉES À PRÉVENIR ET/OU À TRAITER LA FIBROSE, LES CICATRICES OU CHÉLOÏDES HYPERTROPHIQUES[2016/24]
Entry into regional phase04.02.2016National basic fee paid 
04.02.2016Designation fee(s) paid 
04.02.2016Examination fee paid 
Examination procedure04.02.2016Examination requested  [2016/24]
24.06.2016Amendment by applicant (claims and/or description)
30.03.2017Despatch of a communication from the examining division (Time limit: M04)
21.04.2017Reply to a communication from the examining division
14.06.2017Communication of intention to grant the patent
13.10.2017Fee for grant paid
13.10.2017Fee for publishing/printing paid
13.10.2017Receipt of the translation of the claim(s)
Divisional application(s)EP17196300.2  / EP3301112
Opposition(s)23.08.2018No opposition filed within time limit [2018/44]
Fees paidRenewal fee
27.06.2016Renewal fee patent year 03
27.06.2017Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU30.07.2014
AL22.11.2017
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IS22.03.2018
IE30.07.2018
LU30.07.2018
MT30.07.2018
CH31.07.2018
LI31.07.2018
[2020/33]
Former [2020/31]HU30.07.2014
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
MK22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE30.07.2018
LU30.07.2018
MT30.07.2018
CH31.07.2018
LI31.07.2018
Former [2020/30]HU30.07.2014
AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE30.07.2018
LU30.07.2018
MT30.07.2018
CH31.07.2018
LI31.07.2018
Former [2020/28]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
PT22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE30.07.2018
LU30.07.2018
MT30.07.2018
CH31.07.2018
LI31.07.2018
Former [2020/16]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
TR22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE30.07.2018
LU30.07.2018
MT30.07.2018
CH31.07.2018
LI31.07.2018
Former [2020/08]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE30.07.2018
LU30.07.2018
MT30.07.2018
CH31.07.2018
LI31.07.2018
Former [2019/33]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
IE30.07.2018
LU30.07.2018
CH31.07.2018
LI31.07.2018
Former [2019/21]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
LU30.07.2018
CH31.07.2018
LI31.07.2018
Former [2019/17]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
LU30.07.2018
Former [2019/15]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
MC22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/52]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SI22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/40]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RO22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/37]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
PL22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
SM22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/35]AT22.11.2017
CY22.11.2017
CZ22.11.2017
DK22.11.2017
EE22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
RS22.11.2017
SE22.11.2017
SK22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/24]AT22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
LV22.11.2017
NL22.11.2017
RS22.11.2017
SE22.11.2017
BG22.02.2018
NO22.02.2018
GR23.02.2018
Former [2018/23]AT22.11.2017
FI22.11.2017
HR22.11.2017
LT22.11.2017
NL22.11.2017
RS22.11.2017
SE22.11.2017
NO22.02.2018
GR23.02.2018
Former [2018/22]FI22.11.2017
LT22.11.2017
NL22.11.2017
NO22.02.2018
Cited inInternational search[A]WO2009085274  (CODA THERAPEUTICS INC [US], et al) [A] 1-15 * the whole document *;
 [A]  - YING-MEI LIN ET AL, "HIC1 interacts with and modulates the activity of STAT3", CELL CYCLE, (20130715), vol. 12, no. 14, doi:10.4161/cc.25365, ISSN 1538-4101, pages 2266 - 2276, XP055143038 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.4161/cc.25365
 [A]  - JÉRÔME AVOUAC ET AL, "Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis", ARTHRITIS & RHEUMATISM, (20110325), vol. 63, no. 3, doi:10.1002/art.30171, ISSN 0004-3591, pages 800 - 809, XP055112868 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1002/art.30171
 [A]  - TAO LING ET AL, "Role of the JAK-STAT pathway in proliferation and differentiation of human hypertrophic scar fibroblasts induced by connective tissue growth factor.", MOLECULAR MEDICINE REPORTS 2010 NOV-DEC, (201011), vol. 3, no. 6, ISSN 1791-3004, pages 941 - 945, XP002722998 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.3892/mmr.2010.349
 [A]  - JENNIFER M. HAHN ET AL, "Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology", WOUND REPAIR AND REGENERATION, (20130701), vol. 21, no. 4, doi:10.1111/wrr.12060, ISSN 1067-1927, pages 530 - 544, XP055112583 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1111/wrr.12060
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.